Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome-Reference-Cited by-同舟云学术

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome

Published:2017-11-22 Issue:4 Volume:56 Page:614-624
ISSN:1437-4331
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Shi Hui¹,Zheng Hui²,Yin Yu-Feng¹,Hu Qiong-Yi¹,Teng Jia-Lin¹,Sun Yue¹,Liu Hong-Lei¹,Cheng Xiao-Bing¹,Ye Jun-Na¹,Su Yu-Tong¹,Wu Xin-Yao¹,Zhou Jin-Feng³,Norman Gary L.⁴,Gong Hui-Yun⁵,Shi Xin-Ming⁵,Peng Yi-Bing⁵,Wang Xue-Feng⁶,Yang Cheng-De⁷

Affiliation:

1. Department of Rheumatology and Immunology , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , P.R. China

2. Department of Rheumatology and Immunology , Affiliated Hospital of Taishan Medical University , Shandong , P.R. China

3. Werfen Medical Device Trading (Beijing) Co. Ltd. , Beijing , P.R. China

4. INOVA Diagnostics, Inc. , San Diego, CA , USA

5. Department of Laboratory Medicine , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , P.R. China

6. Department of Laboratory Medicine , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , No. 197 Ruijin Second Road, Huangpu District , Shanghai 200025 , P.R. China , Phone: +86 21 54667770, Fax: +86 21 64333548

7. Department of Rheumatology and Immunology , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , No. 197 Ruijin Second Road, Huangpu District , Shanghai 200025 , P.R. China , Phone: +86 21 64370045, Fax: +86 21 34186000

Abstract

Abstract Background: The aim of the study was to determine the prevalence and clinical associations of antiphosphatidylserine/prothrombin antibodies (aPS/PT) with thrombosis and pregnancy loss in Chinese patients with antiphospholipid syndrome (APS) and seronegative APS (SNAPS). Methods: One hundred and eighty six Chinese patients with APS (67 primary, 119 secondary), 48 with SNAPS, 176 disease controls (79 systemic lupus erythematosus [SLE], 29 Sjogren’s syndrome [SS], 30 ankylosing spondylitis [AS], 38 rheumatoid arthritis [RA]) and 90 healthy donors were examined. IgG and IgM aPS/PT, IgG/IgM/IgA anticardiolipin (aCL) and IgG/IgM/IgA anti-β2-glycoprotein I (anti-β2GPI) antibodies were tested by ELISA. Results: One hundred and sixty (86.0%) of APS patients were positive for at least one aPS/PT isotype. One hundred and thirty five (72.6%) were positive for IgG aPS/PT, 124/186 (66.7%) positive for IgM aPS/PT and 99 (53.2%) positive for both. Approximately half of the SNAPS patients were positive for IgG and/or IgM aPS/PT. Highly significant associations between IgG aPS/PT and venous thrombotic events (odds ratio [OR]=6.72) and IgG/IgM aPS/PT and pregnancy loss (OR=9.44) were found. Levels of IgM aPS/PT were significantly different in APS patients with thrombotic manifestations and those with fetal loss (p=0.014). The association between IgG/IgM aPS/PT and lupus anticoagulant (LAC) was highly significant (p<0.001). When both were positive, the OR for APS was 101.6. Notably, 91.95% (80/87) of LAC-positive specimens were positive for IgG and/or IgM aPS/PT, suggesting aPS/PT is an effective option when LAC testing is not available. Conclusions: Anti-PS/PT antibody assays demonstrated high diagnostic performance for Chinese patients with APS, detected some APS patients negative for criteria markers and may serve as potential risk predictors for venous thrombosis and obstetric complications.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2017-0502/pdf

Reference35 articles.

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.

2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309–11.

3. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120–5.

4. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:2149–57.

5. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients;Biomedicines;2023-12-16

2. Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’;Annals of the Rheumatic Diseases;2023-11-21

3. Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome;Clinical Immunology;2023-11

4. Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity;Irish Journal of Medical Science (1971 -);2023-09-22

5. Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity;IRISH J MED SCI;2023